https://gsk8612inhibitor.com/i....nvestigation-effects
The CANagliflozin cardioVascular Assessment Study (CANVAS) explored how canagliflozin impacted PromarkerD score (a standardized measure) over three years among T2D patients. Participants enrolled in the 2008 study, with baseline eGFR of 60 mL/min/1.73 m2 and preserved kidney function, had their PromarkerD scores evaluated at baseline and three years later. An analysis using generalized estimating equations was performed to ascertain the effect of canagliflozin versus placebo on PromarkerD
Like
Comment
Share
